CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← IMPACT BIOMEDICAL INC. (IBO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

IMPACT BIOMEDICAL INC. (IBO)

Pharmaceutical Preparations · market cap $55M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-31 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Impact Biomedical Inc. (IBO) is a ~$402M market-cap pharmaceutical preparations company (~107.8M shares, ~$3.73) whose lead asset, IMP4927, is listed in Phase 3 for ovarian cancer. Our data also shows four Phase 2 entries (IMP9064 in solid tumors; Senaparib/IMP4297 in ovarian and advanced solid tumors). The data is thin: the company description and IMP4927's mechanism are blank, cash is reported as $0.0M, and there are no analyst ratings.
The catalyst path
  • 2026-12-31 (est.)Phase 2 · IMP9064imp 7/10
  • 2027-10-15 (est.)Phase 2 · Senaparibimp 7/10
Pipeline
AssetPhaseIndication
SenaparibPhase 2Ovary Cancer
IMP4927Phase 3Ovarian Cancer
IMP4297Phase 2Ovarian Cancer
IMP9064Phase 2Solid Tumor
IMP4297(senaparib)Phase 2Advanced Solid Tumours
Price & technical context
3-month
-17.6%
6-month
-28.0%
12-month
-24.1%
52-wk range
$2.68–$9.87
vs 50-day MA
+1.2%
vs 200-day MA
-20.9%
Realized vol
115.7%
Max drawdown
-92.7%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for IBO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.